Phase IIa Trial Evaluating the Safety of Intratumoral Injection of NanoPac in Subjects With Locally Advanced Pancreatic Adenocarcinoma
Phase of Trial: Phase II
Latest Information Update: 24 Aug 2018
At a glance
- Drugs Paclitaxel (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- Sponsors Nanology
- 31 Aug 2018 Biomarkers information updated
- 01 May 2018 Planned End Date changed from 1 Jun 2018 to 1 Dec 2019.
- 01 May 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Dec 2019.